{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-23-003305","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.498080+00:00","generated_at":"2026-06-07T20:33:53.913323+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"enGene appoints Ryan Daws as CFO and Head of Business Development; new CMO agreement with Richard Bryce","bullets":["Ryan Daws appointed CFO and Head of Business Development, effective Nov 27, 2023; replaces Alexandre Grassin.","Daws receives $440K base salary, 40% bonus, $143.5K signing bonus, and 232,000 stock options vesting over 4 years.","CMO Richard Bryce enters employment agreement with $450K base, 40% bonus, eligibility for 153,000 stock options in 2024.","Bryce's agreement provides severance: 12 months base salary plus benefits upon termination or change in control.","enGene's lead program EG-70 in pivotal study for BCG-unresponsive NMIBC; interim data read-out expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-23-003305","json":"https://secwatch.observer/filing/0000929638-23-003305.json","markdown":"https://secwatch.observer/filing/0000929638-23-003305.md","text":"https://secwatch.observer/filing/0000929638-23-003305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/0000929638-23-003305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:33:53.913323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ca0075ba8","claim":"Ryan Daws was appointed as Chief Financial Officer and Head of Business Development at enGene Therapeutics Inc..","evidence_excerpt":"On November 27, 2023, Ryan Daws became Chief Financial Officer (“CFO”) and Head of Business Development of enGene Holdings Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/0000929638-23-003305-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Head of Business Development"}],"fact_type":"executive_change"},{"claim_id":"9ff58bb478","claim":"Alexandre Grassin departed as principal financial officer and principal accounting officer at enGene Therapeutics Inc..","evidence_excerpt":"Mr. Daws replaced Alexandre Grassin as the Company’s principal financial officer and principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/0000929638-23-003305-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}